SERA PROGNOSTICS, INC.
Business
Sera Prognostics is a women's health company that develops and commercializes blood-based biomarker tests and predictive analytics to improve maternal and neonatal health. Its first commercial product, the PreTRM test, predicts the risk of spontaneous preterm birth using a proprietary proteomics and bioinformatics platform. The company operates a single reporting segment focused on pregnancy-related diagnostics, with commercialization through healthcare providers, payers, and direct-to-consumer channels in the United States and pursuing international expansion.
Summary from 10-K filed 2026-03-18
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 81,000 | 77,000 | 306,000 | 268,000 | 82,000 | |
| Cost of revenue | 164,000 | 82,000 | 210,000 | — | — | |
| Research and development | 13 | 15 | 15 | 14 | 11 | |
| Selling and marketing | 7 | 6 | 8 | 15 | 10 | |
| General and administrative | 17 | 16 | 16 | 17 | 14 | |
| Total operating expenses | 37 | 37 | 40 | 46 | 35 | |
| Loss from operations | −37 | −37 | −40 | −46 | −35 | |
| Interest expense | −9,000 | −28,000 | −55,000 | — | — | |
| Other income, net | 5 | 4 | 4 | 2 | 1 | |
| Net loss | −32 | −33 | −36 | −44 | −35 | |
| Net loss per share, basic | −0.67 | −0.99 | −1.16 | −1.43 | −2.33 | |
| Net loss per share, diluted | −0.67 | −0.99 | −1.16 | −1.43 | −2.33 | |
| Weighted-average shares outstanding, basic | 48 | 33 | 31 | 31 | 15 | |
| Weighted-average shares outstanding, diluted | 48 | 33 | 31 | 31 | 15 | |
| Unrealized gain on available-for-sale debt securities, net of tax | 202,000 | 75,000 | 966,000 | −798,000 | −183,000 | |
| Total other comprehensive income | 202,000 | 75,000 | 966,000 | −798,000 | −183,000 | |
| Comprehensive loss | −32 | −33 | −35 | −45 | −35 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4 | 4 | 4 | 30 | 59 | |
| Marketable securities | 35 | 42 | 45 | 53 | 46 | |
| Accounts receivable | 12,000 | 34,000 | 160,000 | 113,000 | 27,000 | |
| Prepaid expenses and other current assets | 2 | 1 | 795,000 | 1 | 2 | |
| Total current assets | 41 | 48 | 61 | 90 | 110 | |
| Property and equipment, net | 1 | 1 | 2 | 3 | 2 | |
| Long-term marketable securities | 57 | 22 | 31 | 21 | 35 | |
| Intangible assets, net | 910,000 | 1 | 0 | — | — | |
| Other assets | 3 | 737,000 | 1 | 2 | 157,000 | |
| Total assets | 102 | 73 | 95 | 116 | 147 | |
| Accounts payable | 862,000 | 2 | 1 | 2 | 1 | |
| Accrued and other current liabilities | 3 | 2 | 3 | 4 | 4 | |
| Finance lease obligation, current portion | 2,000 | 194,000 | 440,000 | 464,000 | 74,000 | |
| Deferred revenue | 20 | 20 | 20 | 9 | 3 | |
| Total current liabilities | 24 | 25 | 24 | 16 | 8 | |
| Finance lease obligation, net of current portion | 0 | 2,000 | 196,000 | 626,000 | 54,000 | |
| Operating lease obligation, net of current portion | 2 | 0 | 644,000 | 1 | 0 | |
| Total liabilities | 27 | 25 | 25 | 17 | 8 | |
| Commitments and contingencies (Note 13) | — | — | — | — | — | |
| Common stock, $0.0001 par value; 150,000,000 Class A shares authorized; 37,976,764 and 33,206,909 Class A shares issued and outstanding as of December 31, 2025 and 2024, respectively; 1,500,000 Class B shares authorized; 967,759 Class B shares issued and outstanding as of December 31, 2025 and 2024. | 4,000 | 3,000 | 3,000 | 3,000 | 3,000 | |
| Additional paid-in capital | 387 | 328 | 317 | 311 | 305 | |
| Accumulated other comprehensive income | 262,000 | 60,000 | −15,000 | −981,000 | −183,000 | |
| Accumulated deficit | −312 | −280 | −247 | −211 | −166 | |
| Total stockholders' equity | 75 | 48 | 70 | 99 | 139 | |
| Total liabilities and stockholders' equity | 102 | 73 | 95 | 116 | 147 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 940,000 | 833,000 | 900,000 | 800,000 | 700,000 | |
| Stock-based compensation | 5 | 7 | 5 | 5 | 3 | |
| Non-cash lease expense | 492,000 | 567,000 | 526,000 | 462,000 | 0 | |
| Non-cash investment income, net | 314,000 | −910,000 | −1 | −239,000 | — | |
| Other | −5,000 | −69,000 | 18,000 | −22,000 | 90,000 | |
| Accounts receivable | 22,000 | 126,000 | −47,000 | −86,000 | −25,000 | |
| Other receivables | 19,000 | 11 | −5 | −3 | −3 | |
| Prepaid expenses and other assets | −352,000 | −10,000 | 465,000 | 718,000 | −2 | |
| Accounts payable | −1 | 455,000 | −442,000 | 352,000 | 603,000 | |
| Accrued and other current liabilities | 682,000 | −575,000 | −2 | −514,000 | 1 | |
| Deferred revenue | 92,000 | −12,000 | 11 | 6 | 3 | |
| Net cash used in operating activities | −26 | −14 | −27 | −35 | −32 | |
| Purchases of marketable securities | −88 | −36 | −54 | −48 | −82 | |
| Proceeds from maturities and sales of marketable securities | 60 | 49 | 54 | 54 | 800,000 | |
| Purchases of property and equipment | −726,000 | −56,000 | −128,000 | −791,000 | −1 | |
| Purchase of intangible assets | 0 | −1 | 0 | — | — | |
| Net cash (used in) provided by investing activities | −29 | 12 | 438,000 | 6 | −83 | |
| Proceeds from public offering of common stock, net of issuance costs | 54 | — | — | — | — | |
| Proceeds from exercise of stock options | 507,000 | 3 | 1 | 308,000 | 592,000 | |
| Proceeds from employee stock purchase plan | 103,000 | 147,000 | 123,000 | 0 | — | |
| Finance lease principal payments | −194,000 | −440,000 | −466,000 | −303,000 | −70,000 | |
| Net cash provided by financing activities | 54 | 3 | 752,000 | 5,000 | 160 | |
| Net (decrease) increase in cash and cash equivalents | −99,000 | 163,000 | −26 | −29 | 45 | |
| Cash paid for interest | 9,000 | 28,000 | 55,000 | 48,000 | 1 | |
| Issuance of stock to settle accrued and other current liabilities | 0 | 406,000 | 0 | — | — | |
| Purchases of property and equipment in accounts payable and accrued and other current liabilities | 9,000 | 0 | 20,000 | 0 | 154,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is SERA PROGNOSTICS, INC.'s CIK number?
SERA PROGNOSTICS, INC.'s SEC CIK number is 0001534969 (1534969). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find SERA PROGNOSTICS, INC.'s SEC filings?
All of SERA PROGNOSTICS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did SERA PROGNOSTICS, INC. last report earnings?
SERA PROGNOSTICS, INC. (SERA) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001534969-26-000024). This is SERA PROGNOSTICS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is SERA PROGNOSTICS, INC.'s most recent earnings 8-K?
SERA PROGNOSTICS, INC.'s latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001534969-26-000024. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View SERA PROGNOSTICS, INC.'s latest earnings 8-K →
Look up any company's CIK number →